BioMarin pays USD 275m upfront for early-stage oral HPP bet ALE1

BioMarin Pharmaceutical (Nasdaq: BMRN) has agreed to acquire Alesta Therapeutics for USD 275 million upfront plus up to USD 215 million in development and regulatory milestones, securing ALE1, a Phase I/IIa oral small molecule the company describes as designed to lower excess inorganic pyrophosphate (PPi) through a novel target within the PPi regulatory pathway. If approved, ALE1 would be the first oral therapy for hypophosphatasia (HPP), a rare genetic bone disease currently treated only by subcutaneous injection.

The deal comes after BioMarin discontinued BMN 401, its enzyme replacement therapy for ENPP1 deficiency, following a failed pivotal trial — removing one asset from the Skeletal Conditions Business Unit that ALE1 will now enter. The timing compresses what might otherwise have been a gap in BioMarin's rare bone mineralization pipeline.

ALE1 is currently in a Phase I/IIa study assessing safety, tolerability, and pharmacokinetics/pharmacodynamics in healthy volunteers and adults with HPP. No efficacy data in HPP patients have been disclosed. BioMarin is acquiring before proof-of-concept in patients, paying a front-loaded USD 275 million — 56% of the USD 490 million total — on the strength of preclinical data and the asset's mechanistic differentiation from existing injectable approaches.

The deal is notably front-loaded for an early clinical asset, with the USD 275 million upfront representing 56% of the maximum USD 490 million consideration tied to disclosed upfront, development, and regulatory payments. BioMarin is therefore committing substantial capital before ALE1 has demonstrated clinical efficacy in HPP.

Prior to closing, Alesta will spin out all non-ALE1 assets — including programs reportedly targeting Charcot-Marie-Tooth disease — to a new entity, and all Alesta employees will transfer to that spinout. No Alesta staff will join BioMarin. The structure effectively makes the transaction an acquisition of ALE1 and its associated rights, while allowing Alesta's other programs and employees to continue independently.

Alesta licensed worldwide rights to ALE1, then known as OC-1, from 1cBio in December 2024 and subsequently advanced the program into Phase I/IIa development. 1cBio retained rights to milestones, royalties, and an equity interest in Alesta under the original agreement.

The acquisition is BioMarin's second in its Skeletal Conditions Business Unit within 15 months. In May 2025, the company acquired Inozyme Pharma for approximately USD 270 million to gain INZ-701, an enzyme replacement therapy for ENPP1 deficiency — the same program it subsequently discontinued in August 2026 after the ENERGY 3 pivotal trial met only one of two co-primary endpoints. BioMarin also completed the acquisition of Amicus Therapeutics in April 2026, adding commercial rare disease therapies Galafold and Pombiliti/Opfolda. ALE1 also keeps BioMarin focused on PPi biology, albeit from the opposite direction to BMN 401. ENPP1 deficiency is characterized by abnormally low PPi, while HPP involves accumulation of PPi due to deficient tissue-nonspecific alkaline phosphatase activity, impairing bone mineralization. ALE1 is designed to reduce excess PPi through a different target in the regulatory pathway.

The upfront paid for ALE1 — a Phase I/IIa asset — is nearly identical to what BioMarin paid for Inozyme's Phase III asset. That pricing differential reflects ALE1's positioning as a potential first oral therapy in an indication where the incumbent generates over USD 1 billion annually in subcutaneous injection revenues, rather than conventional clinical de-risking logic. Both boards have approved the transaction, which is expected to close in Q3 2026.

---

Spot something wrong? Report an issue with this article